Request for Cooperation in a Study Entitled
"2019 - Development Study Contributing to Measures against Novel Coronavirus (2019-nCoV) Infection"

Public information on medical research in humans: The National Institute of Infectious Diseases has obtained the approval of the "Ethical Review Board for Medical Research in Humans at the National Institute of Infectious Diseases," and has conducted the following research study regarding measures against the novel coronavirus infection. We ask for your understanding and cooperation.

For further details, please check the following.

If you may apply to a study subject and have any questions regarding that study, please contact the "Contact Information" provided for each study.

Study title:

2019 - Development Study Contributing to Measures against Novel Coronavirus (2019-nCoV) Infection

Study objectives and methods:

The 2019 novel coronavirus infection has become a major global problem, since confirmation of its occurrence, centered in Wuhan City, Hubei, China in December 2019. In order to accurately understand the risk of this infection, it is essential to scrutinize the characteristics and pathogenicity of the virus, and to develop a simple and rapid test system. Accordingly, the remaining samples from those collected to test patients suspected of being infected with the 2019 novel coronavirus were used for the purpose of developing a test system, and to investigate the characteristics and pathogenicity of the virus. The results of this study are expected to be directly linked to measures against the 2019 novel coronavirus infection. Since all samples stored at the National Institute of Infectious Diseases are anonymized when they are sent from medical institutions, individuals cannot be identified. The results of this research study may be used in presentations at academic conferences or in professional journals. However, information that allows the identification of individuals, including names will never be published.

Study subjects and study period:

Patients whose samples were sent for 2019 novel coronavirus testing through medical institutions to the NIID after 2020, and patients aged over 16 whose samples were sent for 2019 novel coronavirus testing through medical institutions to the NIID, before the completion of this study on March 31, 2022.

Samples and information to be used in the study:

The remaining samples for 2019 novel coronavirus testing, provided from contract testing organizations to the NIID (All were anonymized when sent to the NIID, so that individuals cannot be identified; information is included such as age, sex, epidemiological information on the 2019 novel coronavirus infection, medical history, clinical symptoms, clinical course, laboratory test results, and pathogen test results.)

Study organization:

National Institute of Infectious Diseases

Persons responsible for management of samples/information:

Management of information: Takaji Wakita, Director, National Institute of Infectious Diseases

Control of samples: Shutoku Matsuyama, Head of Laboratory-4, Department of Virology III, National Institute of Infectious Diseases

Contact:

1 -1 -23, Toyama, Shinjuku-ku, Tokyo, 162-8640

National Institute of Infectious Diseases

Takaji Wakita (principal investigator)

TEL 03-5285-1111  FAX 03-5285-1189